| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Oaktree Capital · Howard Marks | $9.1M | 0.13% | 9.18M | New | Q2 2026 |
| Renaissance Technologies | $2.5M | 0.00% | 284.50K | −73% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ATEC trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 4, 2026 | Carls Thomas AndrewOfficer | Stock Award(Grant) at price 0.00 per share. | 200K | — |
| Sep 9, 2026 | Miles Patrick SChief Executive Officer | Purchase at price 8.81 per share. | 115K | $1.01M |
| Aug 4, 2026 | Marshall Tyson EliotGeneral Counsel | Sale at price 9.65 per share. | 8.2K | $78.82K |
| Jun 10, 2026 | Mcginnis Karen KDirector | Sale at price 8.01 per share. | 6K | $48.46K |
| Jun 9, 2026 | Blackford Quentin SDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jun 9, 2026 | Demski David MDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jun 9, 2026 | Pelizzon David RDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jun 9, 2026 | Berkowitz MortimeriiiDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jun 9, 2026 | Mcginnis Karen KDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| Jun 9, 2026 | Valentine Keith CDirector | Stock Award(Grant) at price 0.00 per share. | 32K | — |
| May 10, 2026 | Valentine Keith CDirector | Purchase at price 7.00 - 7.54 per share. | 135K | $996.19K |
| Apr 6, 2026 | Marshall Tyson EliotGeneral Counsel | Conversion of Exercise of derivative security at price 1.68 - 3.34 per share. | 102.5K | $258.05K |
| Mar 12, 2026 | Lish ScottChief Operating Officer | Sale at price 12.30 per share. | 260.5K | $3.20M |
| Mar 12, 2026 | Koning John ToddChief Financial Officer | Sale at price 12.36 per share. | 79.8K | $986.19K |
| Mar 10, 2026 | Sponsel DavidOfficer | Sale at price 12.52 per share. | 163.5K | $2.05M |
| Mar 8, 2026 | Hunsaker Craig EOfficer | Stock Gift at price 0.00 per share. | 600 | — |
| Mar 8, 2026 | Hunsaker Craig EOfficer | Sale at price 12.22 - 12.45 per share. | 116.4K | $1.44M |
| Mar 4, 2026 | Marshall Tyson EliotGeneral Counsel | Sale at price 12.49 per share. | 88.8K | $1.11M |
| Feb 24, 2026 | Lish ScottChief Operating Officer | Stock Award(Grant) at price 0.00 per share. | 459.5K | — |
| Feb 24, 2026 | Hunsaker Craig EOfficer | Stock Award(Grant) at price 0.00 per share. | 459.5K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -29.5 | -8.2 | -20.1 | -10.3 | -20.6 | 11.6 | 10.1 | -1.6 | 10.1 | 6.4 | −47.8% | ||
| 2025 | 28.4 | 6.3 | -19.1 | 8.3 | 13.2 | -10.7 | -4.7 | 50.3 | -8.6 | 30.6 | 18.7 | -6.7 | +129.2% |
| 2024 | 6.5 | -16.5 | 2.7 | -8.5 | -23.1 | 7.6 | -3.3 | -31.7 | -19.4 | 41.2 | 33.5 | -12.4 | −39.2% |
| 2023 | 5.4 | 13.7 | 5.3 | -7.4 | 5.0 | 18.6 | -1.7 | -7.5 | -20.7 | -29.2 | 29.3 | 27.3 | +22.3% |
| 2022 | -9.5 | 6.6 | 4.4 | -5.7 | -29.2 | -14.8 | 15.3 | 0.7 | 15.2 | 17.2 | 0.2 | 20.4 | +8.0% |
| 2021 | 2.5 | 7.9 | -1.6 | 1.3 | -9.3 | 5.7 | -3.8 | -1.8 | -15.8 | -3.8 | -5.4 | 3.0 | −21.3% |
| 2020 | -2.0 | -15.9 | -41.0 | 31.3 | -1.8 | 5.6 | 5.7 | 20.5 | 10.9 | 28.6 | 23.0 | 38.3 | +104.5% |
| 2019 | -43.2 | 22.3 | 66.7 | 60.4 | -7.3 | 15.2 | 3.5 | 11.3 | -4.0 | 37.1 | 2.5 | 0.7 | +210.0% |
| 2018 | 20.3 | -0.3 | 0.6 | 19.6 | -0.3 | -22.2 | -9.4 | 30.0 | -4.0 | -11.0 | -9.7 | -15.5 | −13.9% |
| 2017 | -10.0 | 16.6 | -30.9 | -12.9 | -3.9 | -5.1 | -11.9 | 23.9 | 11.9 | 58.8 | -27.0 | 1.5 | −17.1% |
| 2016 | 40.0 | -54.8 | 26.3 | -8.3 | -4.5 | 66.7 | 17.1 | -18.7 | 135.0 | -33.7 | -16.1 | -38.6 | −10.8% |
| 2015 | -9.2 | 13.3 | 0.0 | -2.1 | -4.9 | 2.2 | -1.4 | -58.1 | -42.1 | 6.1 | -34.3 | 30.4 | −78.7% |
| 2014 | 8.0 | -35.0 | 6.4 | -10.0 | 11.1 | 8.7 | -14.1 | 11.4 | 9.0 | -10.6 | -15.8 | 10.2 | −29.9% |
| 2013 | 4.8 | -5.8 | 29.4 | -10.4 | 3.2 | 5.1 | 12.2 | -13.9 | -0.5 | -7.6 | 9.3 | 1.0 | +21.8% |
| 2012 | 2.3 | 6.8 | 26.1 | -8.0 | -24.3 | 11.5 | -4.3 | -5.7 | -0.6 | 4.2 | -0.6 | -3.5 | −4.1% |
| 2011 | -10.7 | 10.4 | 1.5 | 17.8 | 19.2 | -8.2 | -16.1 | -13.4 | -16.6 | -1.4 | -1.9 | -15.7 | −36.3% |
| 2010 | -17.2 | 16.1 | 24.2 | 4.9 | -20.2 | -12.9 | -8.8 | -51.3 | 3.4 | 2.3 | 3.2 | 20.0 | −49.4% |
| 2009 | -7.7 | -23.5 | 6.6 | 15.8 | 7.3 | 50.9 | 12.7 | 22.5 | 0.4 | 3.9 | -5.0 | 17.6 | +127.2% |
| 2008 | 1.4 | 13.1 | -13.1 | -3.8 | 3.1 | -18.1 | 17.2 | 0.2 | -4.0 | -14.6 | -49.4 | 18.1 | −53.4% |
| 2007 | 13.9 | 9.9 | -10.1 | -14.8 | 3.1 | 3.0 | 1.3 | -4.2 | -6.8 | 23.8 | 8.0 | 9.6 | +35.1% |
Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. The company manufactures and sells implants, instruments, imaging equipment, and spare parts. It offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; SafeOp Neural InformatiX System that automates electromyographic, somatosensory evoked potential, and motor evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems. It also provides split-blade retractors; Sigma-ALIF Access System, a procedure-specific access system; spinal implants and fixation systems comprising NanoTec and Invictus, as well as various standalone implants for height restoration and stabilization. In addition, the company provides biologics comprising 3D ProFuse Osteoconductive Bioscaffold; AlphaGRAFT Demineralized Bone Matrix (DBM) comprising demineralized human tissue; BioCORE Moldable Bioactive Graft, a synthetic mineral-collagen composite matrix that can be molded to fit the bone defect; AlphaGRAFT DBM Fibers comprising demineralized fibers; AlphaGRAFT Cellular Bone Matrix (CBM), a growth factor-enriched cellular bone matrix; AlphaGRAFT CBM that is delivered in granular, fiber, or structural form; and Amnioshield Amniotic Tissue Barrier, an allograft for spinal surgical barrier applications. The company sells its products through a network of independent sales agents and direct sales representatives. The company was founded in 1990 and is headquartered in Carlsbad, California.
Buy / hold / sell counts